Menu
← Oncology Approval Tracker
FDA DECISION ·
Albumin-bound paclitaxel (first generic)
paclitaxel protein-bound particles for injectable suspension (albumin-bound) · Jiangsu Hengrui Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
The first generic to the referenced albumin-bound paclitaxel suspension, listed for metastatic breast cancer after combination chemotherapy failure or relapse within six months of adjuvant chemotherapy.
LAMPGEN ANALYSIS
Why it matters
This approval concerns the albumin-bound product and the generic’s labeled breast cancer use.
What research teams should watch
Keep conventional and albumin-bound paclitaxel separate in orders and check the generic label before using a reference-product indication.
PRIMARY RECORDS